S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223.
Grant K.A., Apffelstaedt J.P., Wright C.A., Myburgh E., Pienaar R., De Klerk M., Kotze M.J.
The 70-gene profile classifies approximately 40% of early-stage breast cancer patients as low-risk compared with 15% using conventional criteria. In comparison, more than 60% were shown to be low risk with use of the MPA validated in this study as an appropriate strategy to prevent chemotherapy overtreatment in patients with early-stage breast cancer.